ATNM Positive Sentiment
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Friday, October 24, 2025 BiopharmaWatch Research 1 min read Key Takeaway: Actinium Pharmaceuticals presented promising preclinical data for ATNM-400 at the 32nd Annual Prostate Cancer Foundation Scientific Retreat. This first-in-class radiotherapy targets a novel antigen and demonstrated superior efficacy compared to PSMA-targeted therapies. Notably, ATNM-400 achieved complete tumor regression in a significant percentage of animal models, showcasing its potential in treating resistant prostate cancer.
Full Press Release Details
- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapyand 177Lu-PSMA-617 therapy, enabling potent activity independent of PSMAexpression
- ATNM-400 demonstrated superior efficacy over PSMA-targeted radioligand therapy(177Lu-PSMA-617 and 225Ac-PSMA-617) with enhanced tumor control andprolonged survival in low-PSMA and treatment-resistant models
- Demonstrated durable anti-tumor responses, exceeding those achieved withthe ARPI enzalutamide
- Combination of ATNM-400 with enzalutamide achieved complete tumor regressionin 40% of prostate cancer-bearing animals, demonstrating strong mechanisticsynergy with AR pathway inhibition
NEW YORK,Oct. 24, 2025/PRNewswire/ --Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32ndAnnual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA.